However, GD2 expression levels in TH-MYCN (a transgenic neuroblastoma model driven by tyrosine hydroxylase promoter–driven MYCN overexpression) NBs were previously considered too low for targeting, resulting in the inadequate use of this model for GD2-targeted therapy studies (McNerney et al., 2022). Here, MYCN is linked to neuroblastoma.